Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Sharma P, López-Tarruella S, García-Saenz JA, Khan QJ, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Monte-Millán MD, González-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, González Del Val R, Cortés J, Fuentes-Rivera H, Morales DB, Márquez-Rodas I, Perou CM, Lehn C, Wang YY, Klemp JR, Mammen JV, Wagner JL, Amin AL, O'Dea AP, Heldstab J, Jensen RA, Kimler BF, Godwin AK, Martín M. Sharma P, et al. Among authors: perou cm. Clin Cancer Res. 2018 Dec 1;24(23):5820-5829. doi: 10.1158/1078-0432.CCR-18-0585. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061361 Free PMC article.
Cell-type-specific responses to chemotherapeutics in breast cancer.
Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, Shay JW, Kaufmann WK, Perou CM. Troester MA, et al. Among authors: perou cm. Cancer Res. 2004 Jun 15;64(12):4218-26. doi: 10.1158/0008-5472.CAN-04-0107. Cancer Res. 2004. PMID: 15205334
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Rouzier R, et al. Among authors: perou cm. Clin Cancer Res. 2005 Aug 15;11(16):5678-85. doi: 10.1158/1078-0432.CCR-04-2421. Clin Cancer Res. 2005. PMID: 16115903
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling.
Julka PK, Chacko RT, Nag S, Parshad R, Nair A, Oh DS, Hu Z, Koppiker CB, Nair S, Dawar R, Dhindsa N, Miller ID, Ma D, Lin B, Awasthy B, Perou CM. Julka PK, et al. Among authors: perou cm. Br J Cancer. 2008 Apr 22;98(8):1327-35. doi: 10.1038/sj.bjc.6604322. Epub 2008 Apr 1. Br J Cancer. 2008. PMID: 18382427 Free PMC article. Clinical Trial.
Triple-negative breast cancer: risk factors to potential targets.
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA. Schneider BP, et al. Among authors: perou cm. Clin Cancer Res. 2008 Dec 15;14(24):8010-8. doi: 10.1158/1078-0432.CCR-08-1208. Clin Cancer Res. 2008. PMID: 19088017 Review.
560 results